ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2792

Th22 Cells Are a Potent Inducer of Osteoclastogenesis in Rheumatoid Arthritis

Yusuke Miyazaki1, Shingo Nakayamada2, Satoshi Kubo1, Kazuhisa Nakano2, Kei Sakata3, Shigeru Iwata4, Ippei Miyagawa5 and Yoshiya Tanaka6, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 3The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyshu, Japan, 4First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 5University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 6The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: joint destruction, osteoclastogenesis, rheumatoid arthritis (RA) and synovium, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis I

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: CD4+ T cells can differentiate into functionally distinct subsets and play a pivotal role in rheumatoid arthritis (RA). Th22 cells have been identified as a new subset secreting IL-22. Although elevated levels of IL-22 in the synovial fluids of RA patients were reported, its pathological roles remain unclear. In this study, we examined the function of human Th22 cells, the distribution of Th22 cells in synovial tissues in RA patients, and the influences of Th22 cells on osteoclast differentiation in order to elucidate the role of Th22 cells in RA pathogenesis.

Methods: CD3+ CD4+ CXCR3+ CCR6– (Th1) cells, CD3+ CD4+ CXCR3− CCR4+ CCR6+ CCR10− (Th17) cells, and CD3+ CD4+ CXCR3− CCR4+ CCR6+ CCR10+ (Th22) cells were sorted from the peripheral blood of healthy individuals and the ability of these subsets to produce cytokines were compared. CD3+CD4+IL-22+IL-17–IFN-γ–Th22 cells and chemokine receptor-ligands (CCL17, CCL20, CCL28) in synovial tissues in patients with RA and osteoarthritis (OA) were evaluated by immunohistochemistry. Human monocytes were cultured with IL-22, IL-17 or IFN-γ in the presence of M-CSF and RANKL for 12 days. Th1 cells, Th17 cells or Th22 cells were sorted from peripheral blood and co-cultured with monocytes in the presence of M-CSF and RANKL.

Results: CD3+ CD4+ CCR4+ CCR6+ CCR10+ cells produced neither IFN-γ nor IL-17, but characteristically produced IL-22 alone, and that their ability to produce IL-22 exceeded that of other helper T cell subsets. Th22 cells were markedly infiltrated in synovial tissue in patients with active RA, but not in patients with OA. CCL17, CCL20 and CCL28 were abundantly expressed in RA synovial tissue compared to OA. Actually, by in vitro Trans-well migration assay, Th22 cells efficiently migrated towards CCL28. Addition of IL-22 to the in vitro culture of monocytes with M-CSF and RANKL markedly increased numbers of tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts formation. Contrarily, the addition of IFN-γ to the culture significantly decreased TRAP-positive osteoclasts number, whereas IL-17 had marginal effects. The gene expression of NFATc1 and cathepsin K was significantly increased by addition of IL-22 to the culture in a dose dependent manner. Co-culture of Th22 cells, which were sorted from peripheral blood, with monocytes in the presence of M-CSF and RANKL induced TRAP-positive osteoclasts formation more efficiently than that of either Th1 cells or Th17 cells. IL-22 neutralizing antibody completely inhibited osteoclast formation in co-culture of Th22 cells with monocytes.

Conclusion: Th22 cells, which co-express chemokine receptors CCR4, CCR6 and CCR10, possess strong potency of tissue migration and accumulate into inflamed synovial tissues where the ligands such as CCL28 are highly expressed. The results indicated that Th22 cells have the capacity to promote osteoclast differentiation through production of IL-22. Thus, Th22 cells may play a pivotal role in the pathogenesis of RA by bone resorption in RA synovitis.


Disclosure: Y. Miyazaki, None; S. Nakayamada, Bristol-Myers Squibb, 8; S. Kubo, Bristol-Myers Squibb, 8,Pfizer Inc, 8,Takeda Pharmaceutical Company Ltd, 8; K. Nakano, None; K. Sakata, None; S. Iwata, None; I. Miyagawa, None; Y. Tanaka, Mitsubishi-Tanabe, Takeda, Bristol-Myers, Chugai, Astellas, Abbvie, MSD, Daiichi-Sankyo, Pfizer, Kyowa- Kirin, Eisai, Ono, 2,Daiichi-Sankyo, Astellas, Pfizer, Mitsubishi-Tanabe, Bristol-Myers, Chugai, YL Biologics, Eli Lilly, Sanofi, Janssen, UCB, 8.

To cite this abstract in AMA style:

Miyazaki Y, Nakayamada S, Kubo S, Nakano K, Sakata K, Iwata S, Miyagawa I, Tanaka Y. Th22 Cells Are a Potent Inducer of Osteoclastogenesis in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/th22-cells-are-a-potent-inducer-of-osteoclastogenesis-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/th22-cells-are-a-potent-inducer-of-osteoclastogenesis-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology